cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Viracta Therapeutics Inc
3 own
5 watching
Current Price
$2.06
$-0.01
(-0.48%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
78.08M
52-Week High
52-Week High
5.75
52-Week Low
52-Week Low
1.21
Average Volume
Average Volume
0.09M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization78.08M
icon52-Week High5.75
icon52-Week Low1.21
iconAverage Volume0.09M
iconDividend Yield--
iconP/E Ratio--
What does the Viracta Therapeutics Inc do?
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company s development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Read More
How much money does Viracta Therapeutics Inc make?
News & Events about Viracta Therapeutics Inc.
Globe Newswire
15days ago
Sixth orphan drug designation for Nana-val globally; second granted by the European CommissionSAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients ...
Globe Newswire
26days ago
Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC); enrollment into forth dose level is ongoing Anticipates clinical program updates from pivotal NAVAL-1 study in EBV+ relapsed/...
PR Newswire
4 months ago
Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and...
PR Newswire
5 months ago
Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors PR Newswire SAN DIEGO, Aug. 11, 2022 SAN DIEGO, Aug. 11, 2022 /PRNewswire/ -- ViractaTherapeutics, Inc. (Nasdaq: VIRX), a precision oncology company...
Zolmax
6 months ago
Viracta Therapeutics, Inc. (NASDAQ:VIRX Get Rating) was the target of a significant drop in short interest during the month of June. As of June 30th, there was short interest totalling 998,500 shares, a drop of 48.5% from the June 15th total of 1,940,000 shares. Based on an average trading volume of...
Frequently Asked Questions
Frequently Asked Questions
What is Viracta Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Viracta Therapeutics Inc shares?
plus_minus_icon
How can I buy Viracta Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Viracta Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Viracta Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Viracta Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Viracta Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Viracta Therapeutics Inc?
plus_minus_icon
What percentage is Viracta Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Viracta Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.06
$-0.01
(-0.48%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00